Chugai Seiyaku Kabushiki Kaisha

Chifumi Imai

Tomoyuki Igawa

Tetsuo Kojima

Zenjiro Sampei

Takehisa Kitazawa

Atsushi Muto

Tsukasa Suzuki

Tetsuhiro Soeda

Kazutaka Yoshihashi

Yukiko Nishida

Hitoshi Sasaki

Daisuke Kameoka

Shaw Nishizawa

Masaya Yasutake

Atsushi Saeki

Akira Hayasaka

Masakazu Fukuda

Atsushi Watanabe

The present invention relates to stable antibody-containing solution formulations in which aggregate formation of Emicizumab (ACE910) which is a bispecific antibody functionally substituting for FVIII, is suppressed. Specifically, the present invention relates to the above-mentioned antibody-containing solution formulations of pH 4.5 to 6.5 that contain the aforementioned bispecific antibody at 20 to 180 mg/mL, 10 mM to 40 mM histidine-aspartate buffer, Poloxamer 188 at 0.2 to 1 mg/mL, and 100 mM to 300 mM arginine.

Antibody-containing preparation

Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.

Methods of treatment that include the administration of bispecific antibodies

Bispecific antibodies

Growing community of inventors

Shizuoka, Japan

Chifumi Imai